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Spectrophotometric method for simultaneous 
determination of valsartan and substances from the group 
of statins in binary mixtures
Applicability of derivative spectrophotometry for the de-
termination of valsartan in the presence of a substance 
from the group of statins was checked. The obtained re-
sults indicate that the proposed method may be effective by 
using appropriate derivatives: for valsartan and fluvastatin 
– D1, D2 and D3, for valsartan and pravastatin – D1 and D3, 
for valsartan and atorvastatin – D2 and D3. The method 
was characterized by high sensitivity and accuracy. Line-
arity was maintained in the following ranges: 9.28–32.48 
mg mL–1 for valsartan, 8.16–28.56 mg mL–1 for fluvastatin, 
14.40–39.90 mg mL–1 for atorvastatin and 9.60–48.00 mg mL–1 
for pravastatin. Determination coefficients were in the 
range of 0.989–0.999 depending on the analyte and the or-
der of derivative. The precision of the method was high 
with RSD from 0.1 to 2.5 % and recovery of individual com-
ponents was within the range of 100 ± 5 %. The developed 
method was successfully applied to the determination of 
valsartan combined with fluvastatin, atorvastatin and 
pravastatin in laboratory prepared mixtures and in phar-
maceutical preparations.
Keywords: valsartan, atorvastatin, fluvastatin, pravastatin, 
derivative spectrophotometry
Valsartan (VAL), (S)-3-methyl-2-(N-{[2’-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl] methyl}
pentanamido) butanoic acid, is a cardioprotective drug, specific, selective angiotensin II 
receptor antagonist (ARB, sartan), type AT1. Fluvastatin (FLU), (3R,5S,6E)-7-[3-(4-fluoro-
phenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid, pravastatin (PRV), 
(3R,5R)-3,5-dihydroxy-7-((1R,2S,6S,8R, 8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutano-
yl]oxy}- 1,2,6,7,8,8a-hexahydronaphtha-len-1-yl)-heptanoic acid, and atorvastatin (ATR), (3R,5R)- 
- 7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy 
heptanoic acid, belong to the group of statins (STAT), selective inhibitors of 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMG-CoA reductase). They are commonly used 
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as primary hypolipidemic drugs. Structural formulas of the tested substances are shown 
in Fig. 1.
Substances from the group of angiotensin II receptor antagonists (ARB) and inhibitors 
of 3-hydroxy-3-methylglutaryl-coenzyme A reductase are commonly used in the treat-
ment of hypertension with concomitant dyslipidemia. Extensive research on the use of 
VAL and STAT demonstrated that co-administration of small doses of these substances has 
a beneficial effect on improving the state of the arteries in patients who have changes as-
sociated with age (1), or in the case of changes in the arteries of patients with diagnosed 
diabetes (2). The beneficial effect of the combination of these substances on the reduction 
of oxidative stress in combination with anti-inflammatory effect was also observed when 
compared with the administration of VAL alone (3).
Recent studies of polytherapy with VAL and STAT show that this combination has a 
synergistic effect and may significantly increase the effectiveness of antihypertensive ac-
tivity of VAL (4).
In scientific literature, we can find many monographs on the analysis of sartans, deter-
mination of individual substances, mixtures or combinations with other substances in labo-
ratory prepared mixtures, pharmaceutical preparations and biological material, usually 
blood serum or urine. The most commonly used methods for this purpose were chromato-
graphic methods such as HPTLC and TLC (5, 6), LC (7, 8), HPLC (9) and CE (10, 11). The 
UPLC-MS/MS method was applied for simultaneous determination of telmisartan and hy-
Fig. 1. Chemical structures of valsartan (VAL), fluvastatin (FLU), pravastatin (PRV) and atorvastatin 
(ATR).
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drochlorotiazide in human plasma (12). VAL was also determined by a spectrophotometric 
method (13, 14). Atorvastatin was determined in tablets by a microwell-based spectrophoto-
metric method (15). Analytical aspects relating to the ARB were also reviewed (16, 17).
Chromatographic methods such as HPLC with spectrophotometric detection were 
successfully used for the determination of inhibitors of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase (18–20). Electroanalytical methods (21, 22) and spectrophotometric 
methods were also applied (23). Pharmacokinetics of statins, their metabolites and impuri-
ties were described in review papers by Pasha et al. (24) and Ertürk et al. (25).
Owing to the undeniable synergistic and beneficial effects of polytherapy with VAL 
and STAT, pharmaceutical formulations as mixtures of these substances, in the form of 
two-component medications or polypills, might be expected soon. This was the motif to 
search for a simple, rapid and accurate method for the determination of these substances 
in a mixture. We have developed a derivative spectrophotometric method to be success-
fully applied to the analysis of binary mixtures of VAL and one of the examined statins. 
In the available literature, we have found no reports on spectrophotometric determination 
of binary mixtures described in this paper.
EXPERIMENTAL
Instruments
A spectrophotometer UV-VIS Cary 100 (Varian, Australia), Ultrasonic bath Elma 
(Schmidbauer GmbH, Germany) and centrifuge MPW 54 (MPW Med. Instruments, Po-
land) were used.
Chemicals
USP reference standards used were: valsartan (Sigma-Aldrich, USA), fluvastatin so-
dium (USP Convention, Rockville, MD, USA), pravastatin sodium (Sigma-Aldrich), atorva-
statin calcium (Sigma-Aldrich).
Reagents and methanol of analytical grade quality were used.
Pharmaceutical formulations
 Four pharmaceutical preparations were used: Avasart 160 (manufactured by 
Polfarmex S.A., Poland, one tablet contains 160 mg of VAL), Lescol 20 (produced by Novar-
tis Pharma GmbH, Germany, one capsule contains 21.06 mg of fluvastatin sodium equiva-
lent to 20 mg of fluvastatin free acid), Pravator 20 (manufactured by Ranbaxy Sp. z o.o., 
Poland, one tablet contains 20 mg of pravastatin sodium), Atorvasterol 20 (produced by 
Polpharma SA, Poland, one tablet contains 20 mg of atorvastatin calcium).
Standard and working solutions
Standard solutions of the standard substances of VAL, FLU, PRV and ATR were pre-
pared in methanol.
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For direct measurements, standard solutions were diluted with methanol in order to 
obtain working solutions in the concentration ranges (in μg mL–1): 9.28–32.48 for VAL, 8.16 
–28.56 for FLU, 9.6–48.00 for PRV and 14.40–39.90 for ATR.
Analytical wavelengths for VAL and STAT
Absorption spectra for VAL (g = 3.92 μg mL–1), FLU (g = 20.40 μg mL–1), PRV (g = 18.80 
μg mL–1) and ATR (g = 23.20 μg mL–1) were recorded in UV using methanol as a blank. 
Absorption spectrum of VAL shows a poorly marked maximum at 251 nm, FLV and ATR 
show their maxima close to 251 nm while PRV shows a well-defined maximum at 237 nm. 
The obtained absorption spectra were converted into first, second and third order deriva-
tives. Using the zero-crossing technique, analytical wavelengths were determined for ap-
propriate derivatives and examined substances.
Method validation
The method was validated according to the ICH recommendations (26) and Polish 
Pharmacopoeia (27).
Linearity. – After transformation of the absorption spectra for VAL, FLU, ATR and PRV 
in concentration ranges (in μg mL–1) of 9.28–32.48, 8.16–28.56, 14.40–39.90 and 9.60–48.00, 
resp., into derivative curves D1, D2, and D3, the derivative value was read at the specified 
wavelength and the relationship between the derivative value and concentration was plot-
ted. The following tests were performed in order to verify the model of calibration: Man-
del’s (p < 0.05 indicates the existence of a significant difference between the two models 
compared – linear and quadratic fit; p > 0.05 indicates the equivalence of the two matches), 
Shapiro-Wilk (value of the statistic test W greater than the critical value allows to assume 
normal distribution), the Durbin-Watson and the Lagrange tests. The existence of autocor-
relation of the residuals was verified.
Accuracy and intra-day precision. – The accuracy of the method was checked by deter-
mining the recovery using the standard addition method at three concentration levels (80, 
100 and 120 % of analyte concentration). The intra-day precision was checked at 50, 100 and 
150 % of analyte concentration. All measurements were repeated three times and the re-
sults were calculated using the appropriate regression equation. The obtained results were 
evaluated statistically.
Limit of detection (LOD) and limit of quantitation (LOQ). – LOD and LOQ were calculated 
using the following formulae: LOD = 3.3 SY/a and LOQ = 10 SY/a (SY – residual standard 
deviation of the regression line, a – slope of the calibration line).
Selectivity. – Selectivity of the method with respect to binary mixtures of standard 
substance solutions was tested by determining the lack of influence of the substance co-
present in the mixture on the value of the derivative of the primary component. Selectiv-
ity of the method in relation to a pharmaceutical formulation containing one active sub-
stance was checked by comparing its absorption spectrum after the active substance 
extraction process was performed, with the absorption spectrum of the standard solution 
of similar concentration. No differences confirmed the lack of influence of the excipients.
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Laboratory prepared mixtures containing different ratios of VAL/FLU, VAL/ATR  
and VAL/PRV
Mixtures containing the following ratios of VAL/STAT 2:1; 1:1 and 1:2 were prepared 
in a series of volumetric flasks by accurately transferring different amounts of working 
solutions and filling them with methanol to a specified volume. Absorption spectra were 
then recorded in the range of 200–400 nm. In the next step, absorption spectra were con-
verted into derivatives of an appropriate order and values of derivatives were read at ex-
perimentally chosen wavelengths. The appropriate regression equation was used to calcu-
late the concentration of the compound determined.
Application to the analysis of pharmaceutical formulations
VAL and the corresponding STAT were determined in commercially available phar-
maceutical preparations (Avasart 160, Lescol 20, Pravator 20, Atorvasterol 20) using the 
developed method. Ten tablets of an appropriate preparation were powdered in a mortar 
and a portion of powder corresponding to one tablet was accurately weighed using an 
analytical balance. Weighed samples were transferred into 10.0-mL flasks and extracted 
with 10.0 mL of methanol by immersing them in an ultrasonic bath for 30 min. The extract 
was then centrifuged for 15 min (1500 rpm) and filtered through a syringe filter (0.45 μm). 
Solutions prepared in this way were then diluted to obtain the concentration of the ana-
lyzed substance in the linearity range. VAL and STAT concentrations in the samples were 
calculated using the appropriate regression equation. Five replicates were made for each 
pharmaceutical preparation.
RESULTS AND DISCUSSION
Spectral characteristics
None of the tested substances, with the exception of FLV, have a maximum in the 
range of 270–360 nm that could be used for quantitative analysis. Interference of spectra 
in the range of 200–280 nm makes direct determination of VAL in the presence of STAT 
difficult and does not ensure satisfying results according to the ICH requirements for 
spectrophotometric methods (Fig. 2). Interference of zero-order spectra of analytes sig-
nificantly impedes direct simultaneous determination of VAL in the presence of FLV, PRV 
or ATR. Hence, derivative spectrophotometry with the „zero-crossing” technique was 
used in the course of analysis.
Conversion of zero-order spectra into derivatives causes their significant variation 
and the appearance of maxima that can be used for quantitative analysis of VAL and STAT 
mixtures. After evaluation of the first order (D1), second order (D2) and third order (D3) 
derivatives of the tested spectra and application of the „zero-crossing“ method, it was 
found that in the case of a VAL-FLV mixture the determination may be successfully done 
using D1, D2 and D3 derivatives (Fig. 3).
In the case of the D2 derivative for the VAL-PRV mixture, it was not possible to deter-
mine zeros that could be used for quantitative analysis of the individual components and 
only D1 and D3 derivatives were used for determination (Fig. 4). Derivatives recorded for 
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Fig. 2. Zero-order absorption spectra of VAL (g = 3.92 μg mL–1), FLU (g = 20.40 μg mL–1), PRV (g = 18.80 
μg mL–1) and ATR (g = 23.20 μg mL–1).
Fig. 3. D1, D2, D3 derivatives for standard solutions of VAL (g = 9.28, 13.92, 18.54, 23.20, 27.84, 32.48 
mg mL–1) and FLU (g = 8.16, 12.24, 16.32, 20.40, 24.48, 28.56 mg mL–1).
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the VAL-ATR mixture showed zeros useful for quantitative analysis only in the case of D2 
and D3 derivatives (Fig. 5).
Analysis of the obtained derivatives allowed determining appropriate wavelengths. In 
the case of the determination of VAL and FLV, D1, D2 and D3 derivatives may be used. The 
following wavelengths were determined using the zero crossing method: D1 λ = 234.82 nm, 
D2 λ = 259.04 nm and D3 λ = 265.29 nm for VAL and D1 λ = 339.41 nm, D2 λ = 263.80 nm and 
D3 λ = 271.43 nm for fluvastatin. VAL and PRV can be determined only by using D1 and D3 
derivatives, at the wavelength of D1 l = 235.85 nm and D3 l = 246.28 nm for VAL, and D1 
derivative at λ = 249.29 nm and D3 derivative at λ = 239.90 nm for PRV. A mixture of VAL 
and ATR showed zeros in D2 and D3 derivatives and the optimal wavelengths were: D2 λ 
= 273.20 nm and D3 λ = 245.96 nm for VAL, D2 λ = 246.77 nm and D3 λ = 239.90 nm for ATR. 
In addition, the course of the D3 derivatives has demonstrated the possibility to determine 
ATR or PRV at l = 239.90 nm in ternary mixtures, in the presence of VAL and FLV.
Fig. 4. D1 and D3 derivatives for standard solutions of VAL (g = 9.28, 13.92, 18.54, 23.20, 27.84, 32.48 
mg mL–1) and PRV (g = 9.6, 19.2, 28.8, 38.4, 48.0, 57.60 mg mL–1).
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Validation
Validation results together with statistical evaluation are presented in Tables I and II.
Selectivity. – The absorption spectra recorded for solutions of pharmaceutical prepara-
tions after extraction did not differ from the absorption spectra of standard solutions. At 
the selected wavelengths, no additional extremes were observed that could affect the ob-
tained results during analysis.
Linearity. – Linearity was found in the ranges of 9.28–32.48 μg mL–1 for VAL, 8.16–28.56 
μg mL–1 for FLU, 9.60–48.00 μg mL–1 for PRV and 14.40–39.90 μg mL–1 for ATR. The determi-
nation coefficient for examined substances at the chosen analytical wavelengths was 0.9894–
0.9995. The determined linearity ranges for analytes are given in Tables I and II. The tested 
concentration ranges provided the optimal absorbance values and allowed obtaining accu-
rate analysis results. In order to verify the calibration model, linear and quadratic fits were 
Fig. 5. D2 and D3 derivatives for standard solutions of VAL (g = 9.28, 13.92, 18.54, 23.20, 27.84, 32.48 
mg mL–1) and ATR (g = 14.40, 17.10, 22.80, 28.50, 34.20, 39.90 mg mL–1).
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compared by Mandel’s test and the results for all cases indicated equivalence of quadratic 
and linear models. Linear fit was selected for quantitative analyses. The assumption of nor-
mal distribution of residuals was confirmed by the Shapiro-Wilk test. The hypothesis of the 
lack of autocorrelation of random components was verified by the Durbin-Watson test. The 
results indicated no significant autocorrelation of the residual values for VAL and ATR for 
all derivatives and PRV D1 (l = 249.20 nm). In the case of linearity of FLV (for D1, D2 and D3) 
and PRV for D3 (l = 239.90 nm), the occurrence of significant autocorrelation was observed, 
but we decided to apply the linear fit because of higher values of R2 than in the case of qua-
dratic fit. The Lagrange test was used for the third derivative in the case of FLV (l = 271.41 
nm) and VAL (l = 246.28 nm), since the Durbin-Watson test was not conclusive.
Accuracy. – Percent recovery of the analytes at three concentration levels (80, 100 and 
120 %) was within 100 ± 5 %. It ranged from 98.8–103.2 for VAL and 99.6–100.6 % for FLU 
(D1, D2 and D3), 101.4 % (D1) and 101.2 % (D3) for PRV, while it was 102.6 and 101.7 % (D2 
and D3, resp.) for ATR.
Sensitivity. – The method was characterized by high sensitivity. LOD was in the range 
of 1.57–3.67 μg mL–1 for VAL, 0.85–1.50 μg mL–1 for FLV, 1.35–2.03 μg mL–1 for PRV, 3.00–3.67 
μg mL–1 for ATR and the respective LOQs were: 2.86–8.33 μg mL–1, 2.58–4.54 μg mL–1, 
4.08–6.14 μg mL–1, 9.09–11.1 μg mL–1, depending on the class of the derivative.
Analysis of laboratory prepared mixtures
Based on the determined analytical wavelengths for the individual substances and the 
order of the derivative and using the corresponding regression equations, quantitative anal-
yses of the laboratory prepared mixtures were performed. The composition of mixtures was 
adjusted so that the VAL:STAT ratio was 2:1; 1:1 and 1:2. In this way, the lack of effect of the 
second component on the value of the derivative of the examined substance was also proven, 
even if their relative concentrations were significantly different from each other. This con-
firms the correct choice of the appropriate analytical wavelength. In the case of VAL-FLU, 
the obtained recovery was 97.6–102.2 % for VAL and 95.4–103.0 % for FLU, for VAL-PRV 
98.8–101.2 % for VAL and 97.6–101.2 % for PRV, for VAL-ATR 98.6–102.4% for VAL and 98.6–
102.5 % for ATR. In summary, the obtained results were satisfactorily, ranging between 95 
and 102 %. The obtained results together with statistical evaluation are given in Table III.
Analysis of pharmaceutical preparations
The developed and validated method was applied to determination of active sub-
stances in pharmaceutical preparations. Results of the measurements of particular active 
compounds in Avasart 160, Lescol 20, Pravator 20 and Atorvasterol 20 were within the 
range of 95–105 % of the content declared by the manufacturer. The obtained results were 
characterized by good precision and accuracy, as evidenced by the standard deviation and 
95 % confidence interval presented in Table IV. RSD values were within the range of 0.8–2.1 
%. Assay results and statistical analysis are given in Table IV.
Both the validation parameters of the developed method and the results obtained 
from the assays of the components in mixtures and in pharmaceutical formulations were 
satisfactory and acceptable according to the ICH requirements for spectroscopic methods 
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(26). The previously proposed spectrophotometric methods for the determination of val-
sartan (12) in a narrower linearity range showed similar RSD and LOD values. In this case, 
the analysis was using only the first-order derivative, which in some cases can signifi-
cantly complicate the analysis process. The possibility of selection of the derivative allows 
optimizing the obtained results and selecting the appropriate procedure for a mixture of 
defined composition. Another procedure described in the literature was the spectropho-
tometric method that requires determination of the isosbestic point but the application of 
this procedure may be limited when there is no possibility to determine that point (13). In 
the case of determination of statins in pharmaceutical preparations by a spectrophotomet-
ric method, Ergin et al. (21) used the reaction of derivatization of statins with 7,7,8,8-tetra-
cyanoquinodimethane, which, on the one hand, allowed the use of the VIS analysis but, 
on the other hand, significantly complicated the analysis process compared to the method 
using the zero-crossing technique. The application of separation techniques such as HPLC 
(22) gives a much larger linearity range and better validation parameters (method applied 
for the determinations in human serum) but when it was used for the assay in pharmaceu-
tical formulations, slightly higher  RSD values were obtained than with the spectrophoto-
metric method described above. An additional advantage of the spectrophotometric meth-
od is the low cost and short time of the analysis. In the case of the HPLC method, the 
separation of examined substances on Inertsil ODS 3V column (4.6 × 250 mm, 5 μm) took 
about 40 minutes (22) while the time of spectrophotometric analysis that we propose does 
not exceed 1 min.
Table IV. Determination of valsartan, pravastatin, fluvastatin and atorvastatin in pharmaceutical prepara-
tions by the proposed method
Pharmaceutical 
preparation
Content found 
(mean, n = 5) 
(mg per tablet)
Statistical assessment
D1 D2 D3 D1 D2 D3
Avasart 160 
(VAL) 159.71 160.36 160.37
SD = 1.3
t.SEM0.95 = ± 1.6
RSD = 0.8 %
SD = 1.8
t.SEM0.95 = ± 2.359
RSD = 1.2 %
SD = 1.2
t.SEM0.95 = ± 1.5
RSD =0.8 %
Pravator 20 
(PRV) 20.41 – 20.39
SD = 0.1
t.SEM0.95 = ± 0.2
RSD = 2.0 %
–
SD = 0.2
t.SEM0.95 = ± 0.2
RSD = 1.8 %
Lescol 20 (FLV) 21.99 21.03 21.88
SD = 0.8
t.SEM0.95 = ± 1.0
RSD = 1.5 %
SD = 0.4
t.SEM0.95 = 0.2
RSD = 1.9 %
SD = 0.4
t.SEM0.95 = ± 0.5
RSD = 2.0 %
Atorvasterol 20 
(ATR) – 20.45 20.89 –
SD = 1.0
t.SEM0.95 = ± 0.2
RSD = 1.0 %
SD = 0.9
t.SEM0.95 = ± 0.3
RSD = 1.2 %
t . t . SEM0.95 – margin of error
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Other applications
Analysis of the derivatives showed that the third derivative of the absorption spectra 
of FLV and VAL showed zero at λ = 239.90 nm. At this wavelength for PRV and ATR, the 
extremes occurred that are likely to be used for quantitative analysis of ternary mixtures 
containing FLV, VAL and ATR or FLV, VAL and PRV (Fig. 6).
CONCLUSIONS
The spectrophotometric method for simultaneous determination of a substance from 
the group of angiotensin receptor blockers, valsartan, and statins (fluvastatin, pravastatin 
or atorvastatin) was assessed. Achieving reliable results is possible by derivatization of 
zero-order spectra, using the „zero-crossing“ method and selecting the appropriate order 
of the derivative and wavelength. Fulfilment of these conditions means that the method 
used is accurate, precise, sensitive and specific, as evidenced by the statistical parameters.
Based on the conducted measurements and statistical evaluation of the obtained re-
sults, it can be concluded that the proposed procedures can be useful for quantitative 
analysis of valsartan and statins both in model mixtures and in pharmaceutical prepara-
tions, being an alternative to expensive and time-consuming separation techniques.
The proposed method is simple, rapid, selective and sensitive and may be an alterna-
tive to chromatographic methods.
Fig. 6. D3 derivatives for standard solutions of VAL, FLV, ATR and PRV.
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Acronyms/abbreviations. – VAL – valsartan, ATR – atorvastatin, FLV – fluvastatin, PRV – pravas-
tatin, HMG-CoA – 3-hydroxy-3-methylglutaryl coenzyme-A reductase, STAT – statins, ARB – angio-
tensin receptor blocker.
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